612848-74-5

Usage

Uses

Used in Pharmaceutical Industry:
[4-[[4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]phenylethanedione is used as an intermediate in the preparation of Akti-1/2. Akti-1/2 is a small molecule inhibitor that targets the Akt pathway, which plays a crucial role in cell survival, growth, and metabolism. By inhibiting the Akt pathway, Akti-1/2 has the potential to treat various diseases, including cancer and neurodegenerative disorders.
As an intermediate in the synthesis of Akti-1/2, [4-[[4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]phenylethanedione plays a vital role in the development of new therapeutic agents. Its unique structure and functional groups enable the formation of specific chemical bonds and interactions, which are essential for the biological activity of Akti-1/2.

InChI:InChI=1/C27H25N3O3/c31-25(20-6-2-1-3-7-20)26(32)21-12-10-19(11-13-21)18-29-16-14-22(15-17-29)30-24-9-5-4-8-23(24)28-27(30)33/h1-13,22H,14-18H2,(H,28,33)

Upstream product

• 18189-19-0 (4-(Bromomethyl)phenyl)phenylethanedione 
• 20662-53-7 4-(2-keto-1-benzimidazolinyl)piperidine 

Downstream Products

• 612847-29-7 3-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinoxaline-6-carboxylic Acid 
• 612847-31-1 2-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-3-phenylquinoxaline-6-carboxylic acid 
• 616868-63-4 Akti-2 
• 616868-65-6 C₃₉H₃₉N₇O₂ 
• 1009347-62-9 C₄₁H₄₃N₇O₃ 
• 1009347-37-8 C₄₁H₄₃N₇O₃ 
• 1009347-65-2 C₃₈H₃₉N₇O₂ 

Relevant academic research and scientific papers

INHIBITORS OF AKT ACTIVITY

The instant invention provides for canthine analogs that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Synthesis and biological evaluation of unnatural canthine alkaloids

Employing a 'one-pot' microwave-assisted protocol, unnatural canthine alkaloids with biological activities beyond the natural products have been prepared. This report describes unnatural canthine alkaloid analogs as selective, allosteric Akt kinase inhibitors.

Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors

This letter describes the development of two series of potent and selective allosteric Akt kinase inhibitors that display an unprecedented level of selectivity for either Akt1, Akt2 or both Akt1/Akt2. An iterative analog library synthesis approach quickly provided a highly selective Akt1/Akt2 inhibitor that induces apoptosis in tumor cells and inhibits Akt phosphorylation in vivo.